TerminatedNCT05382650
Survey of Human Rabies Immune Globulin Safety in Children
Studying Rabies
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Methodist Hospital Research Institute
- Principal Investigator
- Michael Sirimaturos, PharmDThe Methodist Hospital Research Institute
- Intervention
- Human rabies immune globulin 300 IU/mL(biological)
- Enrollment
- 35 target
- Eligibility
- 17 years · All sexes
- Timeline
- 2023 – 2025
Study locations (2)
- Houston Methodist, Houston, Texas, United States
- Texas Children's Hospital, Houston, Texas, United States
Collaborators
Grifols Biologicals, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05382650 on ClinicalTrials.govOther trials for Rabies
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE3NCT07500207A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)Changchun BCHT Biotechnology Co.
- ACTIVE NOT RECRUITINGPHASE3NCT07275645A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 YearsAb&B Bio-tech Co., Ltd.JS
- ENROLLING BY INVITATIONPHASE1NCT07338786A Phase I Clinical Trial to Evaluate the Safety of Different Immunization Schedules of a Lyophilized Human Rabies Vaccine (Human Diploid Cell)Changchun BCHT Biotechnology Co.
- RECRUITINGPHASE1NCT07021703A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-driedNingbo Rongan Biological Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1NCT06998004A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy AdultsAstriVax Therapeutics
- ENROLLING BY INVITATIONPHASE3NCT05545371Prevention of Rabies With Four Doses of Rabies VaccineChangchun Zhuoyi Biological Co., Ltd
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04270838A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabGUniversity of Oxford